Cardiac allograft vasculopathy risk factors

Cardiac allograft vasculopathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Differentiating Cardiac allograft vasculopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Coronary Angiography
Intravascular Ultrasound
Optical Coherence Tomography
CT
MRI
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cardiac allograft vasculopathy risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiac allograft vasculopathy risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac allograft vasculopathy risk factors
CDC on Cardiac allograft vasculopathy risk factors
Cardiac allograft vasculopathy risk factors in the news
Blogs on Cardiac allograft vasculopathy risk factors
Directions to Hospitals Treating Cardiac allograft vasculopathy
Risk calculators and risk factors for Cardiac allograft vasculopathy risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]

Overview

Cardiac allograft vasculopathy (CAV) is characterized by concentric intimal proliferation leading to diffuse narrowing of the entire length of the epicardial vessel. Immune mediated processes are thought to be the biggest risk factors driving the process of graft vessel narrowing.

Risk Factors

Few immune mediated risk factors reported include:

• Increased levels of B cell antibodies
• Increased levels of HLA-antibodies
• Acute cellular and humoral mediated rejection
• Sensitization to monoclonal antibody OKT3
• Cytomegalovirus infection
• Elevated soluble interleukin-2 receptor levels

Non-immune risk factors include:

• Hyperlipidemia
• Diabetes mellitus
• Recepient age
• Recepient gender
• Obesity
• Pretranplant diagnosis
• Donor ischemic time

However, LDL and triglycerides as risk factors for CAV have been studied more in depth. LDL oxidation leads to recruitment of macrophages and lymphocytes along with increased expression of HLA antigens and interleukin receptors on T cells. This further accelerates the process of vasculopathy.